A previous study compared SGLT2-I to DPP-4 inhibitor treatment in patients with cirrhosis and type 2 diabetes who were on metformin; this study found a decreased risk of mortality in those with SGLT2-I use but no difference in the risk of developing ascites compared to DPP-4 inhibitor users [30]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.